Stereotaxis Publishes Positive MAGiC Catheter Study Results, Demonstrating High Safety and Efficacy in Treating Arrhythmia

Stereotaxis has published positive results from the MAGiC catheter study, which treated patients with arrhythmia in all four heart chambers. The study concluded with record safety and efficacy for 67 patients, with acute efficacy at 94%. The study's authors have treated over 6,500 robotic procedures with older versions of magnetic catheters. Patient enrollment is still ongoing with sustained efficacy rates.

Stereotaxis Inc. (STXS) recently published positive initial data from its MAGiC catheter study in the Journal of Interventional Cardiac Electrophysiology. The study, titled "First In-Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter," marks the first peer-reviewed clinical evidence supporting the safety and efficacy of the MAGiC catheter. This milestone strengthens Stereotaxis' growing body of clinical validation and supports the company’s broader vision to modernize endovascular intervention through innovative robotic solutions [1].

The MAGiC catheter is the world’s first robotic, fully integrated radiofrequency ablation catheter designed for use with Stereotaxis' Robotic Magnetic Navigation system. The study evaluated the catheter's performance in treating a broad range of arrhythmias in all four chambers of the heart. Initial analysis of 67 patients revealed a strong acute efficacy rate of 94%, with an average skin-to-skin procedure time of 83 minutes and a 1.5% rate of procedure-related adverse events. No adverse events were linked to catheter malfunction [1].

Study authors, with combined experience in over 6,500 robotic procedures using earlier-generation magnetic catheters, reported several performance improvements with MAGiC. These included enhanced catheter stability without the use of support sheaths, steady tip temperatures during ablation, and low irrigation rates that benefit patients with poor cardiac or renal function. The catheter also enabled more efficient and potentially more effective lesion formation [1].

Following the announcement, the company's shares traded flat until yesterday’s closing. Shares have lost 3.5% in the year-to-date period compared with the industry’s 7.4% decline. The S&P 500 has gained 6.3% in the same time frame. The publication of first-in-human clinical results for the MAGiC catheter provides strong validation of Stereotaxis’ technology, enhancing physician confidence and accelerating the adoption of its robotic system. As the first peer-reviewed data confirming both safety and efficacy, this milestone supports commercial momentum ahead of broader regulatory clearances, strengthens the company’s credibility in the electrophysiology market, and positions Stereotaxis to gain share in the high-growth, innovation-driven cardiac ablation segment [1].

Meanwhile, STXS currently has a market capitalization of $189.2 million [1]. The global market for robotic catheterization systems is estimated to be worth $54.4 million in 2025 and is projected to reach $190.2 million by 2035, driven by the growing demand for minimally invasive procedures [2].

References:
[1] https://finance.yahoo.com/news/stereotaxis-reports-positive-initial-data-155100740.html
[2] https://www.tradingview.com/news/zacks:1b9552d39094b:0-stereotaxis-reports-positive-initial-data-from-magic-catheter-trial/